Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: July 23, 2017
What is the competitive landscape for TEVA BRANDED PHARM, and what generic alternatives to TEVA BRANDED PHARM drugs are available?
TEVA BRANDED PHARM has twenty-five approved drugs.| Patents: | 45 |
| Tradenames: | 24 |
| Ingredients: | 14 |
| NDAs: | 25 |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Teva Branded Pharm | PROAIR RESPICLICK | albuterol sulfate | POWDER, METERED;INHALATION | 205636-001 | Mar 31, 2015 | RX | Yes | Yes | 8,651,103 | ► Subscribe | Y | ► Subscribe | |||||||||||||||||
Teva Branded Pharm | ZECUITY | sumatriptan succinate | SYSTEM;IONTOPHORESIS | 202278-001 | Jan 17, 2013 | DISCN | Yes | No | 8,366,600 | ► Subscribe | ► Subscribe | ||||||||||||||||||
Teva Branded Pharm | VANTRELA ER | hydrocodone bitartrate | TABLET, EXTENDED RELEASE;ORAL | 207975-005 | Jan 17, 2017 | RX | Yes | No | 9,572,803 | ► Subscribe | Y | ► Subscribe | |||||||||||||||||
Teva Branded Pharm | ZECUITY | sumatriptan succinate | SYSTEM;IONTOPHORESIS | 202278-001 | Jan 17, 2013 | DISCN | Yes | No | 8,983,594 | ► Subscribe | Y | ► Subscribe | |||||||||||||||||
Teva Branded Pharm | AUSTEDO | deutetrabenazine | TABLET;ORAL | 208082-003 | Apr 3, 2017 | RX | Yes | Yes | 9,233,959 | ► Subscribe | Y | ► Subscribe | |||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Teva Branded Pharm | SEASONALE | ethinyl estradiol; levonorgestrel | TABLET;ORAL | 021544-001 | Sep 5, 2003 | RE39861 | ► Subscribe | ||||||||||||||||||||||
Teva Branded Pharm | QVAR 80 | beclomethasone dipropionate | AEROSOL, METERED;INHALATION | 020911-001 | Sep 15, 2000 | 5,776,432 | ► Subscribe | ||||||||||||||||||||||
Teva Branded Pharm | PROAIR HFA | albuterol sulfate | AEROSOL, METERED;INHALATION | 021457-001 | Oct 29, 2004 | 8,834,849 | ► Subscribe | ||||||||||||||||||||||
Teva Branded Pharm | QNASL | beclomethasone dipropionate | AEROSOL, METERED;NASAL | 202813-001 | Mar 23, 2012 | 5,605,674 | ► Subscribe | ||||||||||||||||||||||
Teva Branded Pharm | QVAR 40 | beclomethasone dipropionate | AEROSOL, METERED;INHALATION | 020911-002 | Sep 15, 2000 | 5,683,677 | ► Subscribe | ||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
levonorgestrel; ethinyl estradiol;ethinyl estradiol | Tablets | 0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg | QUARTETTE | 7/10/2013 |
levonorgestrel;ethinyl estradiol;ethinyl estradiol | Tablets | 0.1 mg/0.02 mg and 0.01 mg | LOSEASONIQUE | 11/16/2009 |
conjugated estrogen (synthetic a) | Tablets | 0.3 mg, 0.45 mg and 0.9 mg | CENESTIN | 3/19/2009 |
conjugated estrogen (synthetic a) | Tablets | 0.625 mg | CENESTIN | 3/2/2009 |
conjugated estrogen (synthetic a) | Tablets | 1.25 mg | CENESTIN | 11/3/2008 |
levonorgestrel; ethinyl estradiol; ethinyl estradiol | Tablets | 0.15 mg/0.03 mg/0.01 mg | SEASONIQUE | 1/22/2008 |
levonorgestrel and ethinyl estradiol | Tablets | 0.15 mg/0.03 mg | SEASONALE | 3/29/2004 |
| Patent Number | Expiration Date |
|---|---|
| ► Subscribe | ► Subscribe |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6,743,413 | Suspension aerosol formulations | ► Subscribe | |||||||||||||||||||||||||||
| 7,749,989 | Estrogenic compounds, methods of using and methods of administering the same | ► Subscribe | |||||||||||||||||||||||||||
| 9,108,010 | Dose counters for inhalers, inhalers and methods of assembly thereof | ► Subscribe | |||||||||||||||||||||||||||
| 7,989,436 | Estrogenic compounds and pharmaceutical formulations comprising the same | ► Subscribe | |||||||||||||||||||||||||||
| 7,772,219 | Methods of hormonal treatment utilizing extended cycle contraceptive regimens | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| South Korea | 100663113 | ► Subscribe | |||||||||||||||||||||||||||
| Eurasian Patent Organization | 201300237 | ► Subscribe | |||||||||||||||||||||||||||
| Canada | 2727927 | ► Subscribe | |||||||||||||||||||||||||||
| Canada | 2582530 | ► Subscribe | |||||||||||||||||||||||||||
| New Zealand | 603398 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C0001 | France | ► Subscribe | PRODUCT NAME: ETHINYLESTRADIOL BETADEX CLATHRATE; NAT. REGISTRATION NO/DATE: NL 32343 20060710; FIRST REGISTRATION: NL - RVG 31781 20050804 | ||||||||||||||||||||||||||
| 2015000093 | Germany | ► Subscribe | PRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129 | ||||||||||||||||||||||||||
| 2009 00017 | Denmark | ► Subscribe | PRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629 | ||||||||||||||||||||||||||
| 00221 | Netherlands | ► Subscribe | PRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307 | ||||||||||||||||||||||||||
| 0160011 00192 | Estonia | ► Subscribe | PRODUCT NAME: LEVONORGESTREEL JA ETUENUEUELOESTRADIOOL;REG NO/DATE: EE 894715 11.11.2015 | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,096 others who get our Drug Patent Expiration Alerts:
